^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Ocrevus (ocrelizumab)

    i
    Other names: PRO 70769, R 1594, RG1594, rhuMab 2H7, PRO70769, OCR, RO4964913, PRO-70769, R1594, RO-4964913, RG 1594, RO 4964913, R-1594, RG-1594
    Associations

    News

    Trials
    Company:
    Biogen, Roche
    Drug class:
    CD20 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2d
    CHIMES: Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab (clinicaltrials.gov)
    P4, N=179, Completed, Genentech, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    Ocrevus (ocrelizumab)
    3d
    People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Northwestern University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Ocrevus (ocrelizumab)
    3d
    Mintaka: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) (clinicaltrials.gov)
    P2, N=360, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Ocrevus (ocrelizumab)
    4d
    OLERO: A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis (clinicaltrials.gov)
    P3, N=1300, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Dec 2029 --> Dec 2027 | Trial primary completion date: Dec 2029 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Ocrevus (ocrelizumab)
    5d
    CONSONANCE: A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis (clinicaltrials.gov)
    P3, N=927, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Jan 2026 --> Nov 2026
    Trial primary completion date
    |
    Ocrevus (ocrelizumab)
    16d
    WINDOCRE: Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial (clinicaltrials.gov)
    P3, N=244, Recruiting, Fondation Ophtalmologique Adolphe de Rothschild | Trial completion date: Nov 2027 --> Nov 2029 | Trial primary completion date: Nov 2027 --> Nov 2029
    Trial completion date • Trial primary completion date • Head-to-Head
    |
    Ocrevus (ocrelizumab)
    1m
    MUSCAT: A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov)
    P3, N=292, Recruiting, Biocad
    New P3 trial
    |
    Ocrevus (ocrelizumab)
    1m
    Effect of Ocrelizumab on Neuroinflammation in Multiple Sclerosis as Measured by 11C-PBR28 MR-PET Imaging of Microglia Activation (clinicaltrials.gov)
    P4, N=22, Completed, Massachusetts General Hospital | Not yet recruiting --> Completed | Trial completion date: Jul 2022 --> Apr 2025
    Trial completion • Trial completion date
    |
    Ocrevus (ocrelizumab)
    2ms
    Mintaka: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) (clinicaltrials.gov)
    P2, N=360, Not yet recruiting, Hoffmann-La Roche
    New P2 trial
    |
    Ocrevus (ocrelizumab)
    2ms
    Cellular and humoral vaccination response under immunotherapies-German consensus on vaccination strategies in neurological autoimmune diseases. (PubMed, Ther Adv Neurol Disord)
    The specific humoral and cellular response to vaccination can be compromised under alemtuzumab, azathioprine, cladribine, cyclophosphamide, CD19/CD20 antibodies (inebilizumab, ocrelizumab, ofatumumab, rituximab, ublituximab), dimethyl fumarate/diroximel fumarate, FcRn inhibitors (efgartigimod, rozanolixizumab), complement C5 inhibitors (eculizumab, ravulizumab, zilucoplan), interleukin-6 receptor antibodies (tocilizumab, satralizumab), intravenous immunoglobulins, long-term steroid administration, methotrexate, mitoxantrone, mycophenolate mofetil, tacrolimus, teriflunomide, tumor necrosis factor-α blockers, and sphingosine-1-phosphate receptor modulators (fingolimod, ozanimod, ponesimod, siponimod), as well as after autologous stem cell transplantation...However, the humoral and cellular vaccination response may be impaired under immunotherapy necessitating close monitoring. Here, we provide applicable recommendations to optimize immunization for individuals receiving immunotherapy due to a neurological autoimmune disease.
    Journal
    |
    IL6R (Interleukin 6 receptor)
    |
    Rituxan (rituximab) • cyclophosphamide • methotrexate • Campath (alemtuzumab) • mitoxantrone • cladribine • Arzerra (ofatumumab) • Briumvi (ublituximab-xiiy) • fingolimod • Actemra IV (tocilizumab) • Ocrevus (ocrelizumab) • Uplizna (inebilizumab-cdon)
    2ms
    BI26 More than skin deep: a case of eosinophilic fasciitis in a patient with relapsing-remitting multiple sclerosis. (PubMed, Br J Dermatol)
    Her disease remains well controlled on methotrexate 15 mg once weekly. While the development of eosinophilic fasciitis in this case was presumed to be idiopathic, to our knowledge, this is the first case of eosinophilic fasciitis developing in the setting of long-term ocrelizumab use.
    Journal
    |
    CRP (C-reactive protein)
    |
    methotrexate • Ocrevus (ocrelizumab)
    2ms
    Effects of Ocrevus in Relapsing Multiple Sclerosis (clinicaltrials.gov)
    P4, N=60, Active, not recruiting, Georgia State University | Trial completion date: Sep 2025 --> Dec 2025
    Trial completion date
    |
    Ocrevus (ocrelizumab)